Emergent Biosolutions (EBS) Competitors $6.94 -0.34 (-4.67%) Closing price 03:59 PM EasternExtended Trading$6.94 +0.00 (+0.07%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EBS vs. JNJ, CLDX, DVAX, INVA, MNKD, NVAX, OPK, GERN, RGLS, and ZBIOShould you be buying Emergent Biosolutions stock or one of its competitors? The main competitors of Emergent Biosolutions include Johnson & Johnson (JNJ), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Innoviva (INVA), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), and Zenas BioPharma (ZBIO). These companies are all part of the "medical" sector. Emergent Biosolutions vs. Its Competitors Johnson & Johnson Celldex Therapeutics Dynavax Technologies Innoviva MannKind Novavax OPKO Health Geron Regulus Therapeutics Zenas BioPharma Emergent Biosolutions (NYSE:EBS) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation. Does the media favor EBS or JNJ? In the previous week, Johnson & Johnson had 157 more articles in the media than Emergent Biosolutions. MarketBeat recorded 159 mentions for Johnson & Johnson and 2 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.14 beat Emergent Biosolutions' score of 0.53 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Emergent Biosolutions 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Johnson & Johnson 104 Very Positive mention(s) 12 Positive mention(s) 22 Neutral mention(s) 8 Negative mention(s) 2 Very Negative mention(s) Positive Do institutionals & insiders believe in EBS or JNJ? 78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 1.2% of Emergent Biosolutions shares are owned by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate EBS or JNJ? Emergent Biosolutions currently has a consensus price target of $14.33, indicating a potential upside of 106.53%. Johnson & Johnson has a consensus price target of $172.87, indicating a potential upside of 5.63%. Given Emergent Biosolutions' stronger consensus rating and higher possible upside, equities research analysts plainly believe Emergent Biosolutions is more favorable than Johnson & Johnson.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Emergent Biosolutions 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Johnson & Johnson 0 Sell rating(s) 11 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.57 Which has more volatility and risk, EBS or JNJ? Emergent Biosolutions has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Is EBS or JNJ more profitable? Johnson & Johnson has a net margin of 25.00% compared to Emergent Biosolutions' net margin of -13.63%. Johnson & Johnson's return on equity of 33.07% beat Emergent Biosolutions' return on equity.Company Net Margins Return on Equity Return on Assets Emergent Biosolutions-13.63% -0.52% -0.17% Johnson & Johnson 25.00%33.07%13.16% Which has higher valuation and earnings, EBS or JNJ? Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEmergent Biosolutions$1.04B0.36-$190.60M-$2.71-2.56Johnson & Johnson$88.82B4.43$14.07B$9.3517.50 SummaryJohnson & Johnson beats Emergent Biosolutions on 12 of the 17 factors compared between the two stocks. Get Emergent Biosolutions News Delivered to You Automatically Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EBS vs. The Competition Export to ExcelMetricEmergent BiosolutionsMED IndustryMedical SectorNYSE ExchangeMarket Cap$395.14M$2.91B$5.52B$20.73BDividend YieldN/A2.45%3.80%3.69%P/E Ratio-2.5619.8828.0427.57Price / Sales0.36305.11429.5359.01Price / Cash3.7943.1635.8422.13Price / Book0.787.678.124.66Net Income-$190.60M-$55.28M$3.25B$994.58M7 Day Performance-5.45%2.50%0.97%-0.29%1 Month Performance10.04%11.70%7.36%4.91%1 Year Performance-39.28%4.89%31.31%10.53% Emergent Biosolutions Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EBSEmergent Biosolutions4.1458 of 5 stars$6.94-4.7%$14.33+106.5%-39.4%$395.14M$1.04B-2.562,420JNJJohnson & Johnson4.7823 of 5 stars$156.91+0.0%$171.00+9.0%+4.1%$377.55B$89.33B17.45138,100Trending NewsEarnings ReportDividend AnnouncementAnalyst ForecastOptions VolumeAnalyst RevisionCLDXCelldex Therapeutics2.4484 of 5 stars$23.36+2.0%$50.11+114.5%-40.8%$1.55B$7.02M-8.65150Positive NewsDVAXDynavax Technologies4.3821 of 5 stars$10.74+1.5%$24.00+123.5%+0.0%$1.29B$294.62M-20.65350INVAInnoviva4.0829 of 5 stars$19.58+4.3%$40.33+106.0%+13.9%$1.23B$358.71M-19.39100Analyst RevisionGap UpMNKDMannKind2.6384 of 5 stars$4.03+6.9%$10.33+156.4%-32.8%$1.22B$285.50M40.30400News CoverageAnalyst UpgradeInsider TradeAnalyst RevisionNVAXNovavax4.3379 of 5 stars$6.97+1.9%$17.00+143.9%-55.8%$1.13B$1.21B2.631,990OPKOPKO Health4.0156 of 5 stars$1.34-0.7%$2.75+105.2%-2.8%$1.06B$713.10M-19.142,997Positive NewsGERNGeron3.46 of 5 stars$1.34+1.5%$4.61+244.1%-72.9%$853.47M$116.29M-6.3870News CoverageRGLSRegulus Therapeutics1.6644 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830ZBIOZenas BioPharma1.5936 of 5 stars$12.82+14.7%$36.67+186.0%N/A$536.26M$5M-3.61N/A Related Companies and Tools Related Companies JNJ Alternatives CLDX Alternatives DVAX Alternatives INVA Alternatives MNKD Alternatives NVAX Alternatives OPK Alternatives GERN Alternatives RGLS Alternatives ZBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:EBS) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent Biosolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent Biosolutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.